Home Nautilus Biotechnology

Nautilus Biotechnology

acquired
Post-IPO Round
Developer of Human Proteome Analysis and Quantification Platforms

Basic Information

Nautilus Biotechnology is revolutionizing biomedical research by providing a high-throughput, low-cost platform for analyzing and quantifying the human proteome. The first-generation platform from Nautilus delivers unparalleled sensitivity that is faster, more comprehensive, and less expensive than current methods, accelerating therapeutic development and bringing true proteomics to the world. This greatly enhances medical diagnostic capabilities and makes personalized and predictive medicine a reality.
Nautilus Biotechnology Inc.
California,United States of America
15~50 people
January 01, 2016
info@nautilus.bio